

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-29 (Cancelled).

30. (Previously presented) A pharmaceutical composition comprising polyclonal F(ab')₂ antibody fragments free from albumin and whole antibodies and substantially free of pyrogens, wherein the F(ab')₂ binds to a purified molecule.

31. (Previously presented) The pharmaceutical composition of claim 30, wherein the purified molecule is a cytokine.

32. (Previously presented) The pharmaceutical composition of claim 31, wherein said cytokine is TNF- α .

33. (Previously presented) The pharmaceutical composition of claim 32, wherein said F(ab')₂ neutralizes said TNF- α .

34. (Previously presented) A pharmaceutical composition comprising polyclonal anti-TNF- α F(ab')₂ antibody fragments free from albumin and whole antibodies and substantially free of pyrogens.

35. (Previously presented) A composition comprising the composition of any of claims 30 to 34, further comprising a pharmaceutically acceptable carrier.

36. (Previously presented) A pharmaceutical composition comprising polyclonal F(ab')₂ antibody fragments free from albumin and whole antibodies and substantially free of pyrogens, wherein the F(ab')₂ antibody fragments are obtained by the method which comprises:

(a) contacting a source of antibody with pepsin under conditions to prepare an antibody digest containing F(ab')₂ fragments and being substantially free of unhydrolyzed antibodies;

(b) treating said antibody digest by two steps of ammonium sulfate precipitation,
i) one step at about 16% to about 22% weight by volume ammonium sulfate; and
ii) another step at about 32% to about 38% weight by volume of ammonium sulfate.

37. (Previously presented) A method of treating a cytokine-mediated immune reaction a patient in need thereof, which comprises parenterally administering to said patient a therapeutically effective amount of the pharmaceutical composition any of claims 30 to 34.

38. (Previously presented) The method of claim 37 wherein said parenteral administration comprises systemic administration.

39. (Previously presented) The method of claim 38, wherein said systemic administration comprises intravenous administration.

40. (Previously presented) The method of claim 38, wherein said systemic administration comprises intramuscular administration.

41. (Previously presented) The method of claim 37, wherein said parenteral administration comprises intraperitoneal administration.

42. (Previously presented) The method of claim 37, wherein said patient is a human who has been exposed to the venom of a poisonous animal.

43. (Previously presented) The method of claim 37, wherein said parenteral administration is repeated at least once.